studies and vice versa. The following review aims to give an overview on recent advances and current knowledge about imaging of CNS abnormalities, including morphology, frequency, and prognosis, in patients with MCDs, relevant for the daily routine.
Diagnosis of MCDs
Diagnosing MCDs relies on clinical, chemical, electrophysiological, histological, biochemical, and genetic investigations. Clinical findings suggesting an MCD include short stature, facial dysmorphism, a history of migraine, strokelike episodes, seizures, cognitive decline, impaired hearing, impaired ocular motility, impaired vision, thyroid dysfunction, hypoparathyroidism, diabetes mellitus, hyponatriemia, hypogonadism, cardiomyopathy, impulse generation or propagation abnormalities, vomiting, gastrointestinal pseudo-obstruction, diarrhea, hepatopathy, anemia, leucopenia, thrombocytopenia, renal insufficiency, myopathy, neuropathy, neuronopathy, or skin changes. Blood chemical investigations additionally may show increased creatine-kinase, lactate, or pyruvate. Urine levels of amino acids and organic acids may be reduced. Lactate and pyruvate may be also elevated in the cerebro-spinal fluid. Nerve conduction studies may indicate polyneuropathy or neuronopathy and electromyography may show myogenic, neurogenic or non-specific changes. Visually or acoustically evoked potentials and electroretinography may be abnormal. Neuroimaging may show abnormalities as described in this review. Muscle biopsy may show ragged-red muscle fibers, reduced cytochrome-C activity, increased SDH-activity, or abnormal mitochondria. Most important for diagnosing MCDs are biochemical investigations of the skeletal muscle or other tissues showing reduced activities of respiratory chain complexes or the PDC. The diagnosis is confirmed by demonstration of a mutation in nDNA or nDNA located genes.
Clinical CNS manifestations of MCDs
Clinical CNS manifestations of MCDs include almost all known CNS abnormalities of other cause ( Table 2 ). The CNS abnormalities in MCDs may result from direct affection on the cerebrum or the supplying vasculature (primary CNS manifestations) or from secondary affection on the CNS by a non-CNS MCD abnormality (secondary CNS manifestations). Secondary CNS manifestations in MCDs include Hashimoto encephalopathy 5 , diabetic encephalopathy, hepatic encephalopathy, renal encephalopathy, arteriosclerosis from arterial hypertension, hyperlipidemia, stroke from extra-or intracerebral stenoses or cardiac embolism, neuronal damage at the infarcted area in stroke-like episodes (SLEs) from lactacidosis 6 , or drugs, which impair mitochondrial functions 7 . Clinical CNS manifestations of MCDs may be associated with or without morphological abnormalities on imaging studies or vice versa. 
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Typical CNS abnormalities in MCD patients
Demyelination. white matter lesions
The most frequent finding in MCDs are focal or widespread white matter lesions (Figure 1) , showing up as high signal on T2 or fluid-attenuated inversion recovery (FLAIR) images on magnetic resonance imaging (MRI) 8, 9 . They may manifest as disseminated glial spots or as widespread, confluent lesions, like in leucodystrophy 10 . They may particularly involve the subcortical, central, or periventricular white matter 10 . White matter lesions may also be found in the basal ganglia (N. caudatus, putamen, globus pallidus), midbrain, pons, or cerebellum 11, 12 . Sometimes white matter lesions are found also in watershed regions 13 . Occasionally, cyst-like lesions occur within abnormal white matter 14 . White matter lesions have been described in patients with MELAS 15 , LS [16] [17] [18] [19] , LHON 20, 21 , KSS 21 , MNGIE 12 , or non-syndromic MCD 22, 23 . Also the chronic stage of stroke-like-lesions (SLL) or endstages of cytotoxic edema may manifest as white matter lesions. An increased blood-brain barrier permeability has been speculated to cause leucodystrophy in MNGIE 10 . There is no strong correlation between the extent of white matter involvement and the clinical manifestations but in single patients cerebral functions deteriorate with progressive extension of the cerebral lesions 14 .
Generally, leucencephalopathy of unknown etiology with a complex neurological picture and multi-system involvement should lead the clinician to suspect a MCD 14 .
Stroke-like lesions (SLLs)
Stroke-like lesions are regarded as manifestations of a vasogenic edema, which does not conform to a distinct vascular territory, concerns the white and grey matter, and shows dynamic changes in intensity and extensiveness over weeks, months, or years 24 . In the acute stage SLLs present as T2-hyperintensities, particularly located in the occipital, parietal, or temporal lobes but occasionally also in the frontal areas ( Figure 2 ) [25] [26] [27] [28] [29] . Occasionally, also the deep grey matter may be involved ( Figure  3 ). Stroke-like lesions show progressive spread into the neighboring areas already during the first days after onset 30, 31 . Unique features of SLLs in the acute stage, in addition to progressive spread, are focal periodic epileptiform discharges, focal hyperperfusion, seen on SPECT studies 24 and perfusion weighted MRI, and laminar cortical necrosis (LCN) 24 . Some reports also demonstrated restricted diffusion within SLLs [32] [33] [34] [35] . The SLLs usually progress up to several weeks after onset 36 . Clinical manifestations of SLLs are known as SLEs and include focal motor or sensory deficits, including hemiparesis, hemiataxia, hemianopsia, bilateral visual loss, and hemi- hypesthesia, which often disappear without sequelae or seizures 37 . The SLEs are frequently transient, non-disabling, and often have a better prognosis than manifestations of an ischemic lesion. Since the clinical manifestations of SLLs mimic cerebral ischemia, they may be easily mixed up with ischemic stroke.
Laminar cortical necrosis
Laminar cortical necrosis (LCN) is a rare imaging and histopathological finding in MCDs, related to conditions of cerebral energy depletion, such as hypoxia, ischemia, or hypoglycemia, either in the perinatal period or later in life and with an increased risk to develop spasticity 38 . Laminar cortical necrosis may also occur in patients with decompensated hepatopathy due to hyperammonemia, ischemic stroke, moyamoya syndrome, meningoencephalitis, shaken baby syndrome, epileptic state, citrullinemia, or posterior reversible encephalopathy syndrome. The syndromic MCD most frequently associated with LCN is MELAS syndrome (Figure 4 ). Laminar cortical necrosis has been also described in a single patient with LS. Morphological features of LCN in MCDs are not at variance to those of LCN in non-MCDs. Clinical correlates of a LCN are spastic motor deficits, decreased intellectual capacity, aphasia, hemianopsia, sensory disturbances, or epilepsy 39 .
Ischemic strokes
Ischemic stroke in MCDs most frequently derives from secondary involvement of extra-or intra-cranial arteries by one of the extracerebral manifestations of an MCD, such as diabetes, arterial hypertension, hyperlipidemia, or cardiac involvement, including atrial fibrillation, cardiomyopathy, or left ventricular hypertrabeculation. Involvement of the endothelium or the vascular smooth muscle cells by the underlying metabolic defect may additionally cause stenosis of small arteries, arterioles or capillaries, resulting in small vessel disease, or lacunar ischemic stroke. Ischemic stroke in MCDs does not differ clinically or morphologically from ischemic stroke in patients without a MCD.
Basal ganglia necrosis
Symmetric necrosis of the basal ganglia, thalami, diencephalon, cerebellum, brainstem, or the spinal cord, showing up as T2-hyperintensities, is the imaging hallmark of Leigh syndrome (LS) and Leigh-like syndrome (LLS) ( Figure 5 ) 18, [40] [41] [42] [43] [44] . These lesions are typically progressive in terms of extension and density. Usually, the basal ganglia are affected before involvement of the brainstem 40 . After initial involvement of the putamen, globi pallidi, caudate nuclei, or the thalami, the substantia nigra, peri-aqueductal gray matter, inferior colliculi, inferior olivary nuclei, or reticular formation may become additionally involved 40 . In the advanced stages of LS, white matter involvement additionally develops 40 . There is no correlation between these lesions on imaging and the clinical course or age at onset 40 . Some patients may show iron deposition within the basal ganglia and others may develop bilateral basal ganglia degeneration, as in Leber's hereditary optic neuropathy (LHON) 45 .
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Figure 3: T2-weighted cerebral MRI (FLAIR) of a patient with MELAS syndrome showing hyerintense lesions in both caudate heads and slight leucaraiosis eight years after onset (TR=300, TE=6000).
Atrophy
Cerebral atrophy is a frequent finding on CNS imaging in MCDs and may be categorized as focal or diffuse, cortical or subcortical, supratentorial or infratentorial, primary or secondary after SLLs. Cortical atrophy may also develop in the chronic stage of LCN 46 . Cortical atrophy is associated with cognitive impairment on neuropsychological testing in the majority of the cases 47, 48 . Diffuse cortical atrophy occurs in up to one third of the patients with encephalomyopathy 10 . Some patients with LS may develop predominant cerebellar atrophy with or without cerebral atrophy 10, 49 . Isolated cerebellar atrophy has been also described in Kearns-Sayre syndrome (KSS), chronic progressive external ophthalmoplegia (CPEO), myoclonic epilepsy with ragged red fibers (MERRF) syndrome, and Alpers syndrome 10, 50 . Focal atrophy may also involve the corpus callosum, the caudate nucleus, the basal ganglia, or the parietal, temporal, or frontal lobe. Atrophy may be the sole imaging finding in up to a quarter of the patients with MCDs 50 .
Hemorrhages
Cerebral hemorrhages in MCDs with CNS involvement may present as cortical or subcortical microhemorrhages but only rarely as severe intra-cerebral mass bleeding with mass effect, or subarachnoid hemorrhage. Microhemorrhages may be due to vascular lesions from endothelial swelling or due to lesions of the blood brain barrier. Microhemorrhages are a non-specific imaging feature in MCDs but have been most frequently described in patients with MELAS syndrome, particularly with laminar cortical necrosis, MERRF syndrome, and nonsyndromic MCDs.
Cysts or lacunas
Intra-cerebral cysts may develop after ischemic, lacunar stroke, within white matter lesions, or as a consequence of developmental abnormalities 51, 52 . Cystic cerebral lesions visible on MRI were particularly reported in patients with MELAS, MERRF, and LS. Lacunas in the basal ganglia are a frequent feature of syndromic, or non-syndromic MCDs.
Cerebral developmental abnormalities
Association of MCDs with cerebral developmental abnormalities are rare 51 . Single cases with MCDs have been described, in which imaging studies revealed microcephaly or neuromigrational abnormalities, such as subependymal cysts, leptomeningeal or subcortical heterotopia (leptomeningeal heterotopia), polymicrogyria (particularly in MELAS) 22, 51, 52 , grossly thickened or undifferentiated cortex 51 , tuberous sclerosis 53 , multifocal cerebral calcifications 51 , agenesis of the corpus callosum, or spongyform changes of the brainstem or cerebellum 51 . Calcifications are most frequently located within the basal ganglia, uni-or bilaterally, but may occasionally occur in other locations. Basal ganglia calcifications are not restricted to a particular MCD but may occur with most of the known syndromes, most frequently, however, with MELAS or KSS 48, 54 . In MELAS the most frequent location of the calcifications is the caudate nucleus, putamen, globus pallidus, or thalamus 51 .
Cerebral artery stenoses and moyamoya disease
Moyamoya disease is characterized by spontaneous, progressive occlusion of the supraclinoidal internal carotid arteries and the proximal median or anterior cerebral arteries leading to the formation of extensive arterial collaterals at the base of the cerebrum 34 . Magnetic resonance angiography may reveal occlusion of the distal internal carotid arteries with development of a collateral circulation (moyamoya disease) and stenosis of the intracerebral arteries 55 . Only in single cases, however, moyamoya has been described in patients with MCDs 34, 56 .
Pituitary gland
Endocrine abnormalities, such as hypothyroidism, hypoparathyroidism, diabetes, hypocorticism, or hypogonadism, are a frequent feature of syndromic and non-syndromic MCDs. Additionally, the pituitary gland may be affected, manifesting as hypopituitarism or morphological abnormalities of the pituitary gland on imaging studies. This is particularly the case with pituitary adenomas, which require surgical intervention after 
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Methods to visualize CNS manifestations of MCDs
All imaging methods used to visualize CNS abnormalities can be also applied to MCD patients (Table 3) . Though all methods visualize certain aspects of CNS abnormalities, some are more important in the daily routine than others due to their different availability and sensitivity and specificity to detect certain abnormalities. Of minor importance is the ultrasound, despite its widespread availability. The most helpful techniques to visualize CNS abnormalities in MCDs are the CT and the MRI. SPECT and PET would be useful, but are hardly applied in the daily routine due to their restricted availability.
Computed tomography (CT)
Computed tomography scans are widely available and useful for showing focal or diffuse atrophy, calcifications, cysts or lacunas, ischemic lesions, hemorrhages, white matter lesions, demyelination, but have their limitations when trying to visualize other abnormalities, such as SLLs 57 , symmetric necrosis of the thalami, basal ganglia, diencephalon, or brainstem in patients with LS or LLS 45 . The CT may show diffuse atrophy or focal atrophy of the supratentorial cortex 22 or the cerebellum 58, 59 , focal or diffuse demyelination, uni-or bilateral calcifications of the basal ganglia, frequently observed in MELAS 54, 59 , dentate nuclei, or the cerebellum 59 , vasogenic edema 60, 61 , bilateral striatal necrosis 59, 62 , malformations 63 such as polymicrogyria 52 or tuberous sclerosis 53 , or macro-or microhemorrhages.
Magnetic resonance imaging (MRI)
The most valuable tool to visualize CNS abnormalities in MCDs is the MRI 50 . Magnetic resonance imaging may show atrophy, SLLs, demyelination, ischemic lesions, hemorrhages, vasogenic edema, LCN, or leucencephalopathy. Acute SLLs manifest on MRI as widespread T2-hyperintensities particularly in the temporo-parietal region 50 . On diffusion weighted imaging (DWI) SLLs present as hyperintensities [27] [28] [29] 33, 35, 64, 65 . Diffusion weighted imaging is regarded as more sensitive than T2-weighted images to demonstrate SLLs 15 . Contrary to ischemic lesions the apparent diffusion coefficient (ADC) is usually increased in acute SLE lesions 27 . The MRI may also show focal cytotoxic edema within a SLL in the acute or subacute stage, manifesting as hyperintensities on DWI but low ADC signals 35 . These lesions may be intermingled with cystic lesions in the chronic stage. SLL may either persist during years or may disappear after weeks, months, or years. Bilateral symmetric involvement of the deep grey matter can be found in up to 50% of patients with MCDs, most frequently in Leigh syndrome 50 . LCN on MRI is characterized by permanent, focal or diffuse cortical high signals on T1-weighted or FLAIR images, which follow the gyral anatomy of the cerebral cortex 39 . In the chronic stage cortical atrophy may develop 46 . In neonates with a MCD cerebral MRI may show agenesia of the corpus callosum, ventriculomegaly, diminished sulcal markings, shallow sulci, polymicrogyria, pachygyria with grossly increased thickness, subcortical or periventricular calcifications, or subependymal cysts 51 . Perfusion-weighted imaging may show hyperintensities corresponding to hyperperfusion during the acute or subacute stage of SLL. Whether SPECT or PET studies are more apt to demonstrate hyperperfusion in MCDs than MRI has not been investigated so far. 
MR-spectroscopy (MRS)
Principally, two techniques are available for MRS, proton-MRS (H-MRS) and phosphorus-MRS (P-MRS). H-MRS
typically shows increased lactate and reduced N-acetyl-aspartate (NAA), glutamate, myo-inositol, cholin, or creatine concentrations within the SLLs (Figure 6 ) 66,67 , most frequently occurring in patients with LS, MELAS, KSS, or MERRF 10 . Similar but less prominent alterations can be found in the grey matter 67 . The most frequent finding on MRS in MCD with CNS involvement is an increased lactate peak 15, 18, 33, 65, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] , which may precede the SLLs 15 . High levels of intra-ventricular lactate are usually associated with severe neurologic impairment 6 . In unaffected areas, the cholin peak, creatine peak, or NAA peak may be reduced 22, 70 . In patients with LS high choline levels were seen in the white matter, most probably related to an ongoing demyelination process 81 . In MELAS patients MRS may show increased alanine and glucose concentrations 82 . In patients with PDC deficiency pyruvate may be increased 82 . Also succinate may be elevated in single MCD patients 84 . The MR spectroscopic imaging allows better spatial resolution than single voxel MRS. A disadvantage of single-voxel H-MRS is that mitochondrial dysfunction often has a patchy regional distribution why lactacidosis may be demonstrated in some areas but not in others 10 . In the absence of a structural abnormality on MRI, sampling of the basal ganglia for MRS is recommended 10 . The CSF or intra-cerebral lactate may not only be elevated in MCDs but also in CNS infections or CNS malignancies. Abnormal P-MRS was particularly reported in LHON 85, 86 .
MR-angiography (MRA)
Magnetic resonance angiography may show short or extended stenoses of the extra-or intracranial arteries. The MRA may also indicate moyamoya syndrome as a rare manifestation of cerebral involvement of an MCD if there are bilateral stenoses of the supraclinoidal parts of the internal carotid arteries.
Single photon emission computed tomography (SPECT)
Investigations by SPECT have been rarely carried out in MCD patients and are conflicting. In patients with an ND1 defect the dopamine transporter SPECT was normal 87 . In MELAS patients with a SLE, the cerebral blood flow has been found increased on Tc-99m HMPAO cerebral SPECT 88 . In acute SLLs hyperperfusion has been documented within the lesions 24 . General hyperperfusion, most pronounced within SLLs, may be found even weeks after a SLE. On the contrary the cerebral blood flow may be decreased in patients with CPEO 24, 89 . Irrespective of whether patients had or had not suffered from SLEs, SPECT may show multiple areas of asymmetrical hypoperfusion, particularly in the posterior or lateral cerebral regions, particularly the temporal lobes. Also crossed-cerebellar diaschisis has been reported 89 .
Positron-emission-tomography (PET)
Positron-emission-tomography studies have been only rarely applied in the diagnostic work-up of CNS involvement of MCDs. In a study on patients with POLG mutations loss of dopaminergic neurons has been demonstrated by PET 90 . PET studies in eight carriers of the A3243G mtDNA mutation showed widespread cortical and basal ganglia metabolic deficits 91 .
Practical implications
One of the most important clinical implications of CNS imaging is the differentiation between multiple sclerosis and MCD. Quite a number of MCD patients are diagnosed as multiple sclerosis since they fulfill the MRI diagnostic criteria but present clinically without spasticity, have polyneuropathy, or occur familiarly. Before diagnosing multiple sclerosis it is important to take findings of the clinical examination, family history, electrophysiology, and muscle biopsy into account. It is also important to differentiate between metabolic and ischemic lesions, since in the presence of SLLs antiepileptic therapy may be helpful, particularly if paroxysmal activity can be recorded on EEG 24 . The SLLs need to be distinguished from progressive, multifocal leucencephalopathy, associated with HIV-positives, BK-virus (BKV) or John Cunningham virus (JCV) infection, or side effects of immune-modulatory therapy with natalizumab or rituximab. Furthermore, it is important to consider MCDs as a differential in patients with juvenile stroke, Parkinson syndrome, other extra-pyramidal syndromes, dementia, psychosis, or epilepsy.
Since the prevalence of MCDs appears much higher than previously thought, particularly non-syndromic MCDs, they should be much more frequently considered as differentials. Indications for an MCD are the presence of CNS abnormalities (dementia, epilepsy, SLLs, ischemic strokes, migraine, cognitive decline, extra-pyramidal abnormalities, optic atrophy, spasticity, hypotonia, respiratory failure), PNS abnormalities (polyneuropathy, myopathy, anterior horn cell disease), endocrine abnormalities (short stature, hypopituitarism, pituitary adenoma, hypothyroidism, hypocorticism, hypogonadism, hypohyperparathyroidism, diabetes, osteoporosis), cardiac abnormalities (cardiomyopathy, left ventricular hypertrabeculation, Takotsubo syndrome, arrhythmias), ocular abnormalities (cataract, glaucoma, retinitis pigmentosa), otologic abnormalities (hypacusis, tinnitus, vertigo), gastrointestinal problems (hepatopathy, pancreatitis, vomiting, diarrhea), kidney problems (renal failure, renal cysts, hypokaliemia, hyponatriemia), hyperlipidemia, hematological abnormalities (anemia, thrombocytopenia, leukopenia, pancytopenia), dermatoses, or atherosclerosis. prevalence of MCDs is rapidly increasing because of increased awareness and sensibility for MCDs, clinicians and radiologists should consider MCDs more frequently as differentials of unexplained CNS imaging findings. Though CNS imaging is helpful to support the diagnosis of an MCD, investigations other than imaging are of paramount importance, before establishing the diagnosis of an MCD. The MCDs cannot be diagnosed using CNS imaging alone.
